T. Limsakun

发表

First‐in‐Human Study to Assess the Safety, Pharmacokinetics, and Pharmacodynamics of an Oral Formulation of DS‐1040, an Inhibitor of the Activated Form of Thrombin‐Activatable Fibrinolysis Inhibitor, in Healthy Subjects

O. Yin, F. Kobayashi, G. Atiee, 2019, Journal of clinical pharmacology.

Efficacy and safety of rVIII-SingleChain: results of a phase 1/3 multicenter clinical trial in severe hemophilia A.

E. Santagostino, L. Boggio, K. Fischer, 2016, Blood.

Safety and Pharmacokinetics of DS‐1040 Drug‐Drug Interactions With Aspirin, Clopidogrel, and Enoxaparin

C. Rambaran, F. Pizzagalli, F. Kobayashi, 2020, Journal of clinical pharmacology.

Phase I studies of the safety, tolerability, pharmacokinetics, and pharmacodynamics of DS‐1211, a tissue‐nonspecific alkaline phosphatase inhibitor

J. Stark, H. Zahir, Sonomi Maruyama, 2022, Clinical and translational science.

Synthesis and biological evaluation of thiol-based inhibitors of glutamate carboxypeptidase II: discovery of an orally active GCP II inhibitor.

Qun Liu, T. Tsukamoto, B. Slusher, 2003, Journal of medicinal chemistry.

Controlled, multidose, pharmacokinetic evaluation of two extended-release carbamazepine formulations (Carbatrol and Tegretol-XR).

D. Mason, R. E. Stevens, T. Limsakun, 1998, Journal of pharmaceutical sciences.

Comparative pharmacokinetics of rVIII‐SingleChain and octocog alfa (Advate®) in patients with severe haemophilia A

P. Neumeister, C. Leissinger, M. Morfini, 2016, Haemophilia : the official journal of the World Federation of Hemophilia.

Pharmacokinetic Results of Two Phase III Clinical Studies of Coagulation Factor IX (Recombinant) Albumin Fusion Protein (rIX-FP) in Previously Treated Patients with Hemophilia B (PROLONG-9FP)

E. Santagostino, A. Feussner, T. Limsakun, 2014 .

A physiologically based pharmacokinetic model for trichloroethylene in the male long-evans rat.

P. Bushnell, J. E. Simmons, J. Raymer, 2002, Toxicological sciences : an official journal of the Society of Toxicology.

Population Pharmacokinetic Modeling and Simulation of Recombinant Single-Chain Factor VIII (r VIII-SingleChain) in Patients with Hemophilia a

D. Bensen-Kennedy, A. Veldman, Ying Zhang, 2014 .

The central nervous system effects, pharmacokinetics and safety of the NAALADase-inhibitor GPI 5693.

D. Hilt, J. Gerven, E. Bortey, 2005, British journal of clinical pharmacology.

Pharmacokinetics and pharmacodynamics of antiulcer agents in llama.

J. M. Christensen, T. Limsakun, B. Smith, 2001, Journal of veterinary pharmacology and therapeutics.

Phase 1 Dose Escalation Study of MDM2 Inhibitor DS-3032b in Patients with Hematological Malignancies - Preliminary Results

M. Andreeff, C. Dinardo, R. Olin, 2016 .

Objectives of Biomarkers in Early Drug Development Biomarkers for Pharmacological Effects Biomarkers for (patho)physiological Principle Biomarkers for Therapeutic Principle Table 1 Number of Tests within Individual Domains Neuropsychological Domains Neuroleptics Selective Serotonin Re-uptake Inhibit

M. Ferrari, F. Zitman, D. Hilt, 2022 .

Efficacy and safety of rVIII-SingleChain: results of a phase 1/3 multicenter clinical trial in severe hemophilia A.

E. Santagostino, L. Boggio, K. Fischer, 2016, Blood.